FDA says ‘no clinical need’ for compounded weight loss drugs

The Food and Drug Administration has proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for making certain compounded versions. The agency has determined that there is no “clinical need” to allow large compounding facilities to make large quantities of medicines from semaglutide, the ingredient in Novo Nordisk’s Wegovy weight loss and Ozempic diabetes treatments, as well as tirzepatide, the ingredient in Eli Lilly’s Mounjaro diabetes drug and Zepbound obesity medicine.

This decision specifically targets compounders known as 503B facilities in regulatory terms, following increasing controversy over their role in making weight loss treatments available in recent years. The FDA’s rationale for this decision, which is seen as a win for Novo and Lilly and will impact choices for consumers, is that these compounders no longer meet the legal requirements to market their products.

The exclusion of these active ingredients from the list of substances for compounded medications is significant as it will impact the availability of certain weight loss and diabetes treatments. This move by the FDA aims to address concerns surrounding the regulation of compounders and ensure that medications are being produced in compliance with legal requirements.

Overall, the FDA’s proposal reflects a shift in the oversight of compounded medications, particularly those containing active ingredients used in popular obesity and diabetes drugs. This decision will likely have implications for both patients and pharmaceutical companies, as it redefines the regulations surrounding the production of certain compounded medications.